Publicaciones en las que colabora con Oscar Briz Sánchez (46)

2024

  1. Sensitization of cholangiocarcinoma cells to chemotherapy through BCRP inhibition with β-caryophyllene oxide

    Biomedicine and Pharmacotherapy, Vol. 170

2023

  1. Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs

    Biomedicine and Pharmacotherapy, Vol. 168

  2. Relevance of the organic anion transporting polypeptide 1B3 (OATP1B3) in the personalized pharmacological treatment of hepatocellular carcinoma

    Biochemical Pharmacology, Vol. 214

  3. Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy

    Cancers, Vol. 15, Núm. 12

  4. Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitors

    Biochemical Pharmacology, Vol. 217

2022

  1. Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers

    Cancers, Vol. 14, Núm. 14

2020

  1. Cellular mechanisms accounting for the refractoriness of colorectal carcinoma to pharmacological treatment

    Cancers, Vol. 12, Núm. 9, pp. 1-34

  2. Molecular bases of drug resistance in hepatocellular carcinoma

    Cancers, Vol. 12, Núm. 6, pp. 1-26

  3. Molecular bases of mechanisms accounting for drug resistance in gastric adenocarcinoma

    Cancers, Vol. 12, Núm. 8, pp. 1-29

  4. Sensitizing gastric adenocarcinoma to chemotherapy by pharmacological manipulation of drug transporters

    Biochemical Pharmacology, Vol. 171

2019

  1. Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy

    Hepatology, Vol. 70, Núm. 4, pp. 1246-1261

  2. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib

    British Journal of Pharmacology, Vol. 176, Núm. 6, pp. 787-800

  3. Mechanisms of anticancer drug resistance in hepatoblastoma

    Cancers, Vol. 11, Núm. 3

  4. Models for understanding resistance to chemotherapy in liver cancer

    Cancers, Vol. 11, Núm. 11

2018

  1. Chemoresistance and chemosensitization in cholangiocarcinoma

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1444-1453

  2. Genetic heterogeneity of SLC22 family of transporters in drug disposition

    Journal of Personalized Medicine, Vol. 8, Núm. 2

  3. Molecular bases of the poor response of liver cancer to chemotherapy

    Clinics and Research in Hepatology and Gastroenterology

  4. Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib

    Oncotarget, Vol. 9, Núm. 47, pp. 28474-28485

2017

  1. Molecular bases of chemoresistance in cholangiocarcinoma

    Current Drug Targets, Vol. 18, Núm. 8, pp. 889-900

  2. Usefulness of the MRP2 promoter to overcome the chemoresistance of gastrointestinal and liver tumors by enhancing the expression of the drug transporter OATP1B1

    Oncotarget, Vol. 8, Núm. 21, pp. 34617-34629